Therapeutic agent, sensitive to metal-salen complex compound, and system for regulation of intracorporeal properties for metal-salen complex compound

FIELD: pharmaceutics.

SUBSTANCE: described is therapeutic agent for treating tumours. Device contains magnetic complex compound “Fe-Salen” as medicinal component, as well as chelating agent. Said agent is used for chelating metal complex compound “Fe-Salen” as sensitive component for suppression of side effects of “Fe-Salen” complex compound. Complex compound “Fe-Salen” is localized in affected area due to action of external magnetic field on body, and after exposure to external magnetic field chelating agent is bound with complex compound “Fe-Salen”, which is released from affected region of body. Chelating agent is either deferasirox or deferoxamine.

EFFECT: use in invention of said chelating agents provides suppression of side effects of “Fe-Salen” complex compound.

4 cl, 2 ex, 2 dwg

 



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (A) or (B) where R1 is benzene, R2 is a hydrogen atom, R3 is independently selected from a group which includes a carboxyl group and carboxylate esters, X is a hydrogen atom, n is independently equal to 1-10, m=2, Y is independently selected from a group which includes a hydrogen atom, polystyrene and SiNH2, and Z is a hydrogen atom.

EFFECT: obtaining novel compounds which can be used to bind metals and/or elements of the main subgroup and removal thereof from liquids, solid substances, gases and/or fabric.

16 cl, 6 dwg, 22 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a pharmaceutical composition in the form of a spray for treating a damage by non-lethal irritants (e.g. pelargonic acid morpholide), containing pediphene in the following proportions, wt/volume %: pediphene hydrochloride 0.01-10.0; sodium chloride 0.1-10.0; water for injections up to 100 ml. What is shown is the efficacy of pediphene in compliance with the declared application ensured by the local anaesthetic effect of the drugs.

EFFECT: drug preparation has no allergenic and immunotoxic properties.

3 dwg, 40 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and medicine and specifically to a novel compound - 6-(thietanyl-3)aminopyrimidine-2,4(1H,3H)-dione of formula (1), which inhibits lipid peroxidation.

EFFECT: obtaining a compound which inhibits lipid peroxidation.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: copolymers of hetero-chain aliphatic poly-N-oxides of general formula (I) , where R=N, CH; x=2-4; y=0, 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n. Copolymers possess anti-oxidant action, therapeutic action as detoxicant and immunomodelling agent. Copolymers of formula (I) can be used as immunomodulating carrier for obtaining vaccinating medication and as carrier of medications for obtaining medications.

EFFECT: copolymers of hetero-chain aliphatic poly-N-oxides represent novel class of compounds possessing wide spectrum of pharmacological and vaccinating action, aimed at increase of safety in application, increase of technological and economical effectiveness and ecological safety of production of medications.

20 cl, 2 dwg, 13 tbl, 22 ex

FIELD: veterinary.

SUBSTANCE: invention concerns animal breeding and veterinary. Method involves application of medicine. Chelavite microelement medication is used as preventive medicine in daily dosage of 0.2-0.4 ml per 10 kg of live weight perorally in the forage for constant application; daily dosage for treatment purposes comprises 0.6-0.8 ml per 10 kg of live weight for a month.

EFFECT: reduced lead and cadmium content in blood, milk and wool of animals, intoxication sign regress.

3 tbl, 2 ex

FIELD: medicine, toxicology.

SUBSTANCE: treatment is carried out for 2 steps wherein in the first step the preparation xydofone is administrated in the dose 10-20 mg per kg of body mass per 24 h by continuous course for 21-30 days, and in the second step the chelate-forming pharmaceutical preparation with the stability constant 15-20 is administrated in the therapeutic doses by fractional schedule for 2-7 days. Invention promotes to the complete elimination of heavy metal salts from the body due to weakly or strongly fixed ions of heavy metals providing by the successive administration of xydofone and the chelate-forming pharmaceutical preparation, and provides membrane-stabilizing effect on renal tissues that, in turn, prevents arising possible iatrogenic complications. Invention can be used in treatment of chronic intoxication with heavy metals.

EFFECT: improved and enhanced effectiveness of treatment.

3 cl, 2 tbl

FIELD: coordination compounds synthesis.

SUBSTANCE: invention provides complex comprising calcium and [[(4R)-4[bis[carboxy.kappa.O)methyl]amino-.kappa.N]-6,9-bis[carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecane-11-ylic acid-.kappa.N6,.kappa.N9,-kappa.011]-oxydato(6-)]-,6H, (MS-325) or its salt with physiologically acceptable cation in each case containing essentially no Gf-MS-325. Also described are pharmaceutical agent based on compounds according to claim 1 and a method for preparing galena composition, complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent reducing effect produced by heavy metals as well as complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent suitable for NMR diagnostics and/or diagnostic radiology, a method for amplifying patient's image in NMR tomography based on compounds according to claim 1 and above defined complex or its salt with physiologically acceptable cation in each case containing essentially no visualizing metal chelates and MS-325.

EFFECT: increased assortment of complexes with useful medicine-destination properties.

14 cl, 4 dwg, 30 ex

FIELD: medicine.

SUBSTANCE: method involves a combined administration of the preparations Enterosgel, Kudesan and Pantogam. Enterosgel is administered orally in the form of gel 30 minutes before meals in a dose of 1 teaspoon two times a day for 7 days. Kudesan is also administered orally during meals before noon in an age dose of: 10-16 drops (15-24 mg) in the children aged 5 through 7 years old, 16-20 drops (24-30 mg) in the children aged 8 through 10 years old, pre-dissolved in a small amount of boiled water or other beverage of room temperature, once a day in the course of 30 days. Pantogam is administered orally 15-20 minutes after meals in an age dose of: 500 mg 2 times a day in the children aged 5 through 7 years old, 500 mg 3 times a day in the children aged 8 through 10 years old in the course of 30 days.

EFFECT: complex administration regiment provides the effective correction of cognitive disorders in the given group of children by a synergetic detoxification, antioxidant and neuroprotective action of its components.

3 cl, 4 tbl

FIELD: chemistry.

SUBSTANCE: application of 5% water solution of sodium and potassium salts of humic acids, obtained from leonardite brown coal, in dose 10.0 mg/kg as membrane-protective preparation.

EFFECT: application of composition described above makes it possible to extend arsenal of membrane-protective preparations from low-toxic, cheap, available natural raw material.

2 dwg, 2 ex

FIELD: pharmacology.

SUBSTANCE: agent possessing detoxification activity, containing succinic acid, 10% ethanol extract of propolis, polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 4000, Cremophor CO-40, Tween-80 and purified water in certain proportions.

EFFECT: agent possesses the detoxification action, the uniform release of the active substances and the pronounced prolonged action.

2 cl, 4 dwg, 4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to radiation and experimental biology, biotechnology and medicine, namely to means of radiological protection and to stimulators of colony formation of stem cells. Invention can be used in research and clinical practice for protection of living organisms in case of exposure to ionising radiation, in emergency and military medicine, in case of emergency situations as means for protection against radiation injury. Claimed is application of preparation gamma-plant as radioprotector with colony-stimulating properties for increasing survival and improving state of organisms, subjected to irradiation. Gamma-plant is non-toxic polysaccharide of vegetable origin, registered by Ministry of Health of the Russian Federation and allowed for medical application; Gamma-plant is included into Russian Pharmacopoeia in section FG-9 "non-narcotic analgesics".

EFFECT: invention makes it possible to increase efficiency of colony formation of stem cells in spleen 2,0-2,3 times, increases survival of experimental animals to 95% with coefficient of dose reduction factor DRF, equal 2-2,2.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: medicine.

SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.

EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulatory composition for injection into a mammal. The immunomodulatory composition for injection into a mammal containing a hydrolysate prepared by acid and/or enzymatic hydrolysis of one or more bioresources specified in a group consisting of bivalve molluscs, annelids, leeches, and water taken in certain proportions. A method for preparing the immunomodulatory composition for injection into a mammal. A method of treating a pathological condition in a mammal in need thereof involving the injections of the immunomodulatory composition into the above mammal. Using the composition for normalising metabolism into the mammal in need thereof.

EFFECT: composition enables extending the range of products with immunomodulatory activity for injections.

19 cl, 7 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

EFFECT: improvement of efficiency of the method.

FIELD: medicine.

SUBSTANCE: group of inventions relates to veterinary and medicine, in particular to obtaining and application of biopreparations for immunotherapy of ecopathologies. The group of inventions includes obtaining a protein antigen from a mixture of anatoxins from three enteropathogenic virulent strains of a pathogen of escherichiosis of calves E.coli No. 378, 379, 380 by their growing on Hottinger medium with further addition of 0.4-0.5% formalin, following thermostating for 10-12 days and cooling the mixture of anatoxins with a sterile solution of aluminium hydroxide, after that obtaining radioantigen from E.coli "PL-6" by growing cultures on a meat infusion agar with further washing away a biomass by a physiological solution and irradiation of the obtained suspension with a concentration of 1.2·1010 m.c./cm3 on a gamma-installation in a dose of 140-150 Gr with following thermostating and extraction of radiotoxin with 70% acidified with 0.05% hydrochloric acid to pH 5.5 ethanol, following evaporation of the exractant to the initial volume, after that, obtaining protein-cadmium radioantigen first by preliminary dechlorination of cadmium chloride, obtaining cadmium hydroxide, addition into the obtained 2.7% solution of the antigen of 0.77% solution of cadmium hydroxide in a ratio of 1:1 with following thermostating at a temperature of 37°C for 30 minutes, evaporation and dissolution of the residue to 12.8% concentration, further obtaining protein-cadmium radioantigen by an addition of 1.2% solution of a mixture of three anatoxins of E.coli and 12.8% solution of cadmium radioantigen in a ratio of 1:9, conjugation of components at room temperature for 8-10 hours, standardisation by a dry substance to 10% concentration and pouring into vials, and storage at a temperature of 4-6°C. The group of inventions also relates to a method of treating radiation, chemical and/or bacteriological damage to an organism by introduction of 10% solution of complex protein-cadmium radioantigen.

EFFECT: application of the group of inventions is effective in treatment of radiation, chemical and/or biological damage.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.

EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.

27 cl, 8 dwg, 21 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to 2-(3-amino-1-(2,4-difluorophenyl)-1H-1,2,4-triazol-5-yl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-carboxamide. As well as to a pharmaceutical composition containing the above compound, to the use thereof and a set for treating.

EFFECT: 2-(3-amino-1-(2,4-difluorophenyl)-1H-1,2,4-triazol-5-yl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-carboxamide inhibiting PI3 kinase (PI3K).

6 cl, 15 dwg, 1 tbl, 610 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to the field of biotechnology. Claimed are versions of a humanised anti-CD79b antibody, each of which is characterised by the presence of a light and heavy chain and a set of 6 CDR with a determined amino acid sequence. An epitope of the antibody from 11 amino acids is determined by the Biacore method. Disclosed are: an immunoconjugate of the antibody with a medication or means for inhibiting cell growth, where the antibody is bound with means covalently, and versions of the composition, based on an effective quantity of the immunoconjugate or the antibody, used for inhibiting B-cell proliferation; as well as a method of determining CD79b in a sample with the application of the antibody. Described are: an antibody-coding polynucleotide, as well as an expression vector and an isolated cell, containing the vector for obtaining the antibody. Disclosed are versions of applying the antibody or immunoconjugate for obtaining the medication for inhibiting the growth of CD79b-expressing cells for the treatment of an individual, affected with cancer, for the treatment of proliferative disease or for inhibiting B-cell proliferation.

EFFECT: invention provides novel antibodies, which can find further application in the therapy of proliferative CD79b-associated diseases.

91 cl, 8 tbl, 9 ex, 20 dwg

Up!